Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase 1 Sickle Cell Clear all

Conditions: Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
Interventions: Exa-cel; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York + 4 more

Conditions: Sickle Cell Disease
Interventions: Zileuton; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Renal Impairment
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Lake Forest, California • Tustin, California • Miami, Florida + 1 more

Conditions: Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions: Thiotepa--single daily dose, Thiotepa--escalated dose; Drug
Lead sponsor: University of Florida; Other
Eligibility: 3 Months to 39 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sickling Disorder Due to Hemoglobin S
Interventions: 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging; Drug · Radiation · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: nula-cel Drug Product; Genetic
Lead sponsor: Kamau Therapeutics; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • St Louis, Missouri + 2 more

Conditions: Healthy, Sickle Cell Anemia
Interventions: Placebo, PF-07209326; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more

Conditions: Sickle Cell Disease
Interventions: BEAM-101; Biological
Lead sponsor: Beam Therapeutics Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 14 more

Conditions: Sickle Cell Disease
Interventions: Plerixafor, Busulfan, BIVV003; Biological · Drug · Genetic
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Oakland, California • Sacramento, California • Atlanta, Georgia + 2 more

Conditions: Healthy Adult Subjects, Sickle Cell Disease
Interventions: FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Overland Park, Kansas

Conditions: Sickle Cell Disease
Interventions: Placebo, Zoledronic Acid; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sickle Cell Disease
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: Intravenous citrulline; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 6 Years to 50 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Sickle Cell Anemia
Interventions: Measurement of carbon monoxide level in exhaled breath; Other
Lead sponsor: Ashutosh Lal; Other
Eligibility: 5 Years to 14 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Oakland, California

Conditions: Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa; Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 2 Months to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease, Hemolytic Anemia
Interventions: Mitapivat; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemoglobin SC Disease, Sickle Cell Anemia
Interventions: Recombinant-methionyl human stem cell factor; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Hemoglobinopathies
Interventions: EDIT-301; Genetic
Lead sponsor: Editas Medicine, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: Pociredir oral capsule(s); Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 11 more

Conditions: Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions: Buprenorphine Buccal Film [Belbuca]; Drug
Lead sponsor: Natasha Archer; Other
Eligibility: 12 Years to 22 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers, Anemia, Sickle Cell
Interventions: AG-946, AG-946 Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York + 4 more

Conditions: Sickle Cell Disease
Interventions: Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus; Procedure · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 16 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease
Interventions: CSL889; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 5 more

Conditions: Sickle Cell Disease
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease

Study of GBT021601 in Participants With Renal Impairment

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Safety, Tolerability and Pharmacokinetics of FTX-6058

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects